These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 20100958

  • 1. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.
    J Clin Oncol; 2010 Feb 20; 28(6):918-27. PubMed ID: 20100958
    [Abstract] [Full Text] [Related]

  • 2. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R.
    Lancet Oncol; 2011 Aug 20; 12(8):795-805. PubMed ID: 21782507
    [Abstract] [Full Text] [Related]

  • 3. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.
    J Clin Oncol; 2011 Nov 01; 29(31):4113-20. PubMed ID: 21969500
    [Abstract] [Full Text] [Related]

  • 4. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D.
    J Clin Oncol; 2010 Feb 20; 28(6):911-7. PubMed ID: 20100966
    [Abstract] [Full Text] [Related]

  • 5. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES.
    J Clin Oncol; 2010 Feb 10; 28(5):744-52. PubMed ID: 20038723
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.
    J Thorac Oncol; 2008 Dec 10; 3(12):1446-53. PubMed ID: 19057271
    [Abstract] [Full Text] [Related]

  • 7. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
    Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR.
    J Clin Oncol; 2010 Nov 01; 28(31):4747-54. PubMed ID: 20921467
    [Abstract] [Full Text] [Related]

  • 8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 01; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 9. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.
    J Clin Oncol; 2011 Jul 20; 29(21):2866-74. PubMed ID: 21670455
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.
    Clin Lung Cancer; 2014 Jan 20; 15(1):86-92. PubMed ID: 24139827
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 20; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec 20; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 13. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR.
    Lancet Oncol; 2018 Jan 20; 19(1):101-114. PubMed ID: 29169877
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M, Swiss Group for Clinical Cancer Research (SAKK).
    Lung Cancer; 2012 Dec 20; 78(3):239-44. PubMed ID: 23009726
    [Abstract] [Full Text] [Related]

  • 15. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 10; 27(35):5924-30. PubMed ID: 19884556
    [Abstract] [Full Text] [Related]

  • 16. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
    Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR.
    J Clin Oncol; 2008 Jul 10; 26(20):3351-7. PubMed ID: 18612151
    [Abstract] [Full Text] [Related]

  • 17. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
    Wu JY, Yang CH, Hsu YC, Yu CJ, Chang SH, Shih JY, Yang PC.
    Clin Lung Cancer; 2010 Jul 01; 11(4):257-63. PubMed ID: 20630828
    [Abstract] [Full Text] [Related]

  • 18. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S.
    Lung Cancer; 2015 Feb 01; 87(2):136-40. PubMed ID: 25553650
    [Abstract] [Full Text] [Related]

  • 19. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
    Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE, Cancer, Leukemia Group B, Chicago, IL.
    J Thorac Oncol; 2010 Sep 01; 5(9):1382-90. PubMed ID: 20686428
    [Abstract] [Full Text] [Related]

  • 20. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.
    Eur J Cancer; 2010 Jul 01; 46(11):1997-2009. PubMed ID: 20413299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.